Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3526 |
|
| Actual shortage: | 232 (7%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3280 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (12%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-TRYPTOPHAN | 500MG | CAPSULE | Resolved | 2022-05-06 | 2022-06-17 | 160144 |
| APO-TRYPTOPHAN | 500MG | TABLET | Resolved | 2023-04-06 | 2023-05-12 | 188949 |
| APO-TRYPTOPHAN | 500MG | TABLET | Resolved | 2024-01-26 | 2024-04-05 | 217469 |
| APO-TRYPTOPHAN | 1G | TABLET | Resolved | 2024-02-23 | 2024-04-05 | 220468 |
| APO-VALACYCLOVIR | 500MG | TABLET | Resolved | 2017-03-20 | 2017-03-24 | 3539 |
| APO-VALACYCLOVIR | 500MG | TABLET | Resolved | 2017-10-18 | 2018-01-31 | 26224 |
| APO-VALACYCLOVIR | 1000MG | TABLET | Resolved | 2017-10-23 | 2018-01-31 | 26662 |
| APO-VALACYCLOVIR | 500MG | TABLET | Resolved | 2018-02-01 | 2018-09-12 | 38001 |
| APO-VALACYCLOVIR | 1000MG | TABLET | Resolved | 2018-03-20 | 2019-01-18 | 43519 |
| APO-VALACYCLOVIR | 500MG | TABLET | Resolved | 2018-04-16 | 2018-05-22 | 46006 |
| APO-VALACYCLOVIR | 500MG | TABLET | Resolved | 2018-10-19 | 2018-11-22 | 65005 |
| APO-VALACYCLOVIR | 500MG | TABLET | Resolved | 2019-05-01 | 2019-06-17 | 82903 |
| APO-VALACYCLOVIR | 500MG | TABLET | Resolved | 2020-05-08 | 2020-06-15 | 114324 |
| APO-VALACYCLOVIR | 500MG | TABLET | Resolved | 2021-08-03 | 2021-08-16 | 143404 |
| APO-VALACYCLOVIR | 1000MG | TABLET | Resolved | 2023-07-27 | 2023-08-23 | 200191 |
| APO-VALACYCLOVIR | 1000MG | TABLET | Resolved | 2023-11-10 | 2024-02-02 | 209961 |
| APO-VALACYCLOVIR | 500MG | TABLET | Resolved | 2023-11-17 | 2024-02-02 | 210725 |
| APO-VALACYCLOVIR | 500MG | TABLET | Resolved | 2024-05-03 | 2025-01-03 | 227031 |
| APO-VALACYCLOVIR | 1000MG | TABLET | Resolved | 2024-05-10 | 2025-03-14 | 227714 |
| APO-VALACYCLOVIR | 500MG | TABLET | Resolved | 2024-06-13 | 2025-03-07 | 230350 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |